When Effectiveness Isn't Enough: Four Case Studies of Insurance Coverage for Behavioral Interventions Addressing Chronic Disease

Top Things to Know

Effectiveness evidence may be necessary but not sufficient for payer adoption; studies demonstrating cost-effectiveness, return on investment, scalability, and participant engagement are also likely to influence coverage decisions.

The case studies suggest that favorable policy environments, including Medicare benefit categories, national coverage determinations, preventive-service mandates, and Medicaid demonstration authorities, can accelerate coverage of behavioral and nutrition-related interventions.

Researchers may strengthen the case for coverage by generating evidence that demonstrates not only prevention benefits but also the ability of interventions to manage existing chronic conditions, improve healthcare utilization, and produce measurable savings within payer-relevant time horizons of approximately 1 to 3 years.

Summary of Conclusion/Findings

This policy analysis examined insurance coverage pathways for four behavioral interventions relevant to chronic disease prevention and management: the Diabetes Prevention Program (DPP), Ornish Lifestyle Medicine, Intensive Behavioral Therapy (IBT) for obesity, and SilverSneakers. Rather than evaluating clinical effectiveness directly, the authors reviewed public coverage determinations and interviewed 10 payer stakeholders to understand why some interventions achieve broad insurance coverage while others do not. The review found that strong evidence of effectiveness alone was generally insufficient for coverage decisions; payers also considered cost-effectiveness, expected return on investment, scalability, beneficiary engagement, and alignment with policy priorities. Across the case studies, broad coverage often followed the accumulation of effectiveness and economic evidence, supportive policy actions such as Affordable Care Act preventive-service requirements or Medicare coverage determinations, and the existence of practical implementation and billing pathways. The authors argue that Food Is Medicine and other behavioral interventions may benefit from generating more evidence on treatment and chronic disease management outcomes, comparative effectiveness, and near-term economic impacts because payers frequently view these programs through a prevention lens and prioritize short-term financial returns.